Stay updated on Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.

Latest updates to the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe esophageal cancer trial record is displayed with its study details, participant criteria, locations, outcome measures, publications, and supporting documents. The record identifies the study as completed and no longer recruiting participants.SummaryDifference100%

- Check20 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page. Its footer revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check27 days agoChange DetectedA notice announces that NIH is transitioning its terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.SummaryDifference1%

- Check34 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2. The page otherwise continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study record page now loads a 403 error instead of the trial details, indicating the page is inaccessible. This prevents users from viewing the study's design, eligibility, locations, and outcomes on that page.SummaryDifference18%

Stay in the know with updates to Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy of Nivolumab and Ipilimumab in Esophageal Cancer Clinical Trial page.